No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
001		A-01	Sabir	Soomro	Pakistan	Liver Diseases In Pregnancy: Trends And Their Consequence In Mother And Child
002	۲	A-02	Talal Khurshid	Bhatti	Pakistan	Assessment of severity of Acute Liver Injury and its outcome in patients with Dengue Fever in Lahore and Rawalpindi
003	Suppor	A-03	Wenyu	Wu	China	Chemokine receptor CCR5 and its corresponding chemokine contributes to virus-induced liver injury via conventional NK cells recruitment
004	iver	A-04	Rifaldy	Fajar	Indonesia	Diagnosis of Liver Disease based on Artificial Intelligence Systems using the Decision Tree Algorithm Implementation
005	cial L	A-05	Ying	Han	China	Evaluation of the differential diagnosis value of PIVKA-II in patients with liver disease
006	d Artific	A-06	Smith	Kerdsin	Thailand	Factors associated with death and respiratory failure among patients with acute liver injury. Somdejprachaotaksin Maharaj Hospital, 2020
007	ure anc	A-07	Hanisha	Khemani	Pakistan	Fulminant Hepatic Failure Etiology, Clinical Manifestations, and Outcome: An Experience of Tertiary Care Hospital of Karachi, Pakistan.
008	r Fail	A-08	Smith	Kerdsin	Thailand	Risk factor and severity of acute liver injury between non-chronic liver disease and chronic liver disease
009	Acute Liver Failure and Artificial Liver Support	A-09	Siwaporn	Chainuvati	Thailand	Risk of the Development of Acute-on-Chronic Liver Failure and Overall Mortality among Nonalcoholic Steatohepatitis-related Cirrhosis Patients with Acute Decompensation
010	Acu	A-10	Thaninee	Prasoppokakorn	Thailand	Validation of Prognostic Scores to Predict Short-term Mortality in Acute-on-Chronic Liver Failure Among Patients with Hepatitis B infection: A Multicenter Study
011		A-11	SMITKUMAR	VAGHASIA	India	Sarcoidosis Presenting As Acute Liver Failure— The First Case Report
012	Clinical I	B-01	Tongluk	Teerasarntipan	Thailand	Clinical outcomes of acute decompensation and acute-on-chronic liver failure in patients with alcohol-related liver disease: a multicenter study
013	s: Clir :al	B-03	Do Seon	Song	South Korea	Rifaximin treatment in patients with severe alcoholic hepatitis; a multicenter, open-label, pilot randomized controlled trial
014	sease	B-04	Gireesh	G N	India	Significance of red cell distribution(RDW) in predicting prognosis & mortality in alcoholic cirrhosis of liver
015	: Liver Diseases: nd Experimenta	B-05	Wenyu	Wu	China	Up-regulation of Fgl2 induced by chronic ethanol consumption combined with HBV promotes hepatic macrophage M1-polarization and lipid metabolism disorder
016	Alcoholic L and	B-06	Ajay	Duseja	India	Utility of point shear wave elastography done at Day 28 and Day 90 in prognosticating patients with alcohol related patients with Acute-on-chronic liver failure
017	Alc	B-07	Neeraj	Nagaich	India	WPSU (wellness programme for substance user) - for alcohol relapse prevention: A Ray of Hope in dark
018	iology, angiocyte verimental	C-01	Zhenpeng	Huang	China	Acute Stress Disorder Decreased Gallbladder Interstitial Cells of Cajal
019	Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis	C-02	Natthaya	Chuaypen	Thailand	Proteomic Profiling of Liver Tissue Specimens identify Novel Phosphoproteins in Patients with Intrahepatic Cholangiocarcinoma

No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
020		D-01	Shizhu	Jin	China	Comprehensive analysis of differentially expressed transcriptome with ceRNA networks in a mouse model of liver cirrhosis
021		D-02	Filiz	Akyuz	Turkey	Could Cell-Free DNA And Methylations In RASSF1 And CDKN2AIP Genes Be New Biomarkers In The Diagnosis Of HCC? (Scientific)
022	ology	D-03	Wirin	Bowonsomsarit	Thailand	Fried mung bean (Vigna radiata) and roasted black sesame (Sesamum Indicum) supplement to slow down diabetic kidney and fatty liver
023	Cell and Molecular Biology	D-04	Shizhu	Jin	China	From Hair to Pancreas: Transplanted Hair Follicle Mesenchymal Stem Cells Express Pancreatic Progenitor Cell Markers in a Rat Model of Acute Pancreatitis
024	Molec	D-05	Shizhu	Jin	China	Hair Follicle Mesenchymal Stem Cells Ameliorate Acute Pancreatitis by Differentiating into Pancreatic Progenitor Cells and Reducing Pancreatic Cell Death in Rats
025	ell anc	D-06	Stephanie	Johanes	Indonesia	Hematopoietic Stem Cells Therapy In Patients With End Stage Liver Disease: A Systematic Review Of Randomized Controlled Trial
026	O	D-07	Cheuk-Yan	Wong	Hong Kong	Role of lumican in the metastasis of hepatocellular carcinoma
027		D-08	Shizhu	Jin	China	Therapeutic effect of tanshinone IIA by acting on endogenous stem cells in a rat model of liver cirrhosis
028		D-09	Panas	Lertprapai	Thailand	A comparison of propofol and desflurane anesthesia on miRNA profiles after major hepatic resection in patients with hepatocellular carcinoma.
029	ision	E-01	Gaixia	нЕ	China	Hyaluronan-mediated motility receptor confers a pro-tumor immune microenvironment to support the tumor progression in hepatocellular carcinoma
030	Prec ne	E-02	Dan	Duan	China	Influence of TLR7 polymorphism and sex on pharmacodynamic response to TLR7 agonist (RO7020531)
031	ics and Pr Medicine	E-03	Aleksandr	Abramov	Russian Federation	liver cancer and atherosclerosis are interconnected through the microRNA
032	nics Me	E-04	Pattapon	Kunadirek	Thailand	Profiling of cell-free DNA using Whole-exome sequencing in patients with Hepatocellular carcinoma in Thailand
033	Genomics and Precision Medicine	E-05	Chih-Yang	Hsiao	Taiwan	The significance of quantified extracellular matrix features in patients with hepatocellular carcinoma after curative liver resection
034	d cine	E-06	Pattapon	Kunadirek	Thailand	Transcriptomic analyses reveal cancer-induce genes in PBMCs of Hepatocellular carcinoma for early diagnosis and prognosis
035		E-07	Wenyu	Wu	China	Transcriptomic Characterization Reveals Prognostic Molecular Signatures of Sorafenib Resistance in Hepatocellular Carcinoma
036	omic on N	E-08	Natthaya	Chuaypen	Thailand	Diagnostic performance of PIVKA-II and AFP in relation to underlying etiological factors of hepatocellular carcinoma
037	Genomics an Precision Medi	E-09	Natthaya	Chuaypen	Thailand	Circulating miR-122 levels at baseline predict overall survival of patients with hepatocellular carcinoma treated with transarterial chemoembolization
038	and	F-01	Natthaya	Chuaypen	Thailand	Improvement of Gut Diversity and Composition after Direct-Acting Antivirals in HCV-Infected Patients with or without HIV Coinfection
039	: Liver Axis a Microbiome	F-02	Han	Wang	China	Observation of the clinical features of bacterial liver abscess with endogenous endophthalmitis
040	iver	F-03	Rajendra	Patel	India	Prevalence And Predictive Factors Of Small Intestinal Bacterial Overgrowth (Sibo) In Patients With Cirrhosis Of Liver
041	Gut Liver Axis and Microbiome	F-04	Thananya	Jinato	Thailand	The alteration of gut microbiota composition in patients with hepatitis C virus (HCV) monoinfection and human immunodeficiency virus (HIV) coinfection.

No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
042		G-01	Ying	Liu	China	Application effect of case management model in the nursing of the patients with hepatic encephalopathy
043		G-02	Pakanat	Decharatanachart	Thailand	Application of Artificial Intelligence in Chronic Liver Diseases: A Systematic Review and Meta-analysis
044		G-03	Glaiza	Ranges	Philippines	Assessment of the Quality of Life of Chronic Liver Disease Patients using the Filipino Versions of CLDQ and HADS
045	ے	G-04	Jitendra	Jha	India	BICEPS - another score for the Assessment of Prognosis in Liver Cirrhosis
046	earcl	G-05	William Chi Wai	WONG	Hong Kong	Crowdsourcing to Promote Hepatitis C Testing and Linkage-to- care in China: Randomized Controlled Trial Interim report
047	Res	G-06	Jalpa	Devi	Pakistan	Lower GI Endoscopy-Indications and findings in a Tertiary Care Hospital
048	vices	G-07	Chee-Kiat	Tan	Singapore	Public Awareness and Knowledge on Liver Disease and Liver Health in Singapore
049	Ser	G-08	Yue-yong	Zhu	China	Socioeconomic development status and the global burden of acute hepatitis, 1990–2017
050	Health Services Research	G-09	Daniel	Burkholder	United States	Specificity and positive predictive value of International Classification of Diseases-10 diagnosis codes for cirrhosis
051	I	G-10	Farheen Lubna	Hashmi	Pakistan	Spectrum of Liver Diseases in tertiary care hospital – Observation from GI and Liver disease out patients.
052		G-11	Jin	Youn	South Korea	Understanding the Knowledge, Attitudes and Practices of the Public towards Liver Disease in Malaysia
053	G	G-12	Jalpa	Devi	Pakistan	Upper GI Endoscopy-Indications and findings in a Tertiary Care Hospital
054		G-13	Aleksandra	Bodys-Pełka	Poland	Alterations in the cardiovascular system in patients with cirrhosis - assessment of a haemodynamic profile.
055	th es rch	G-13	Saurabh	Gaur	India	Crush Smear Cytology -An Adjunct To Biopsy In Gastrointestinal Malignancies
056	Health Services Research	G-14	Srinivas	Reddy	India	Prevalence of periodontal disease in patients with liver cirrhosis and its influence on the short-term outcome of the disease.
057		H-01	Shalini	Sethi	United States	96-week Efficacy and Safety of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch vs. Continued TDF Treatment among Virologically-suppressed Hepatitis B patients of Asian Ethnicity (AE)
058		H-02	Juan	Zhao	China	A real-world clinical study of lipid changes on TAF treatment in Chinese chronic hepatitis B patients with diabetes
059		H-03	Chunlan	Zhang	China	A Real-World Study of Treatment of Sofosbuvir/Velpatasvir on Chronic hepatitis C in Guangdong Province of China
060	itis [H-04	Heejoon	Jang	South Korea	Association of Aspirin with Hepatocellular Carcinoma in Patients with Chronic Hepatitis B with or without Cirrhosis
061	Hepatitis B and Hepatitis	H-05	Engin	ALTINTAS	Turkey	Association of genetic polymorphisms of OATP with susceptibility to hepatocellular carcinoma in Hepatitis C patients who achieved SVR by direct acting antivirals.
062	is B and	H-06	Ming-Ying	Lu	Taiwan	Changing epidemiology and viral interplay among hepatitis B, C and D in the inmates without human immunodeficiency virus infection of Taiwan Prison
063	oatit	H-07	Muhammad Ali	Qadeer	Pakistan	Characteristics of hepatitis D in young adults
064	Heg	H-08	Cheuk Fung	Yip	Hong Kong	Chronic hepatitis B does not increase the risk of adverse clinical outcomes in patients with COVID-19: a territory-wide cohort of 2,256 patients
065		H-09	Bogi	Wibowo	Indonesia	Comparison of HBV DNA Supression and Renal Safety Profile in Chronic Hepatitis B Patients at Saiful Anwar Hospital Malang
066		H-10	Shi	Weifeng	China	Comparison of the pharmacokinetic parameters of ASC18 tablets (ravidasvir and sofosbuvir fixed dose combination) with reference tablets (ravidasvir, sofosbuvir) for hepatitis treatment

No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
067		H-11	Dong	Ji	China	DAAs and NAFLD are associated with increased incidence of Hepatocellular carcinoma in patients with chronic HCV infection after sustained virologic response: a prospective multi-center study
068		H-12	Bogi	Wibowo	Indonesia	Duration of Denial-Acceptance of The Kübler-Ross Cycle in Patients After Diagnosed Hepatitis B
069		H-13	Amr	Elsayed	Egypt	During the era of pandemic COVID19, Is Telemedicine effective in the follow up of HCV patients receiving direct anti viral therapy?
070		H-14	Feng	Liu	China	Dynamic fibrosis features in HCV post-treatment liver biopsies and its interpretation
071		H-15	Talal Khurshid	Bhatti	Pakistan	Dyspepsia in Hepatitis C Patients
072		H-16	Lu	Junfeng	China	Early antiviral efficacy of tenofovir alafenamide in initial treatment of patients with chronic hepatitis B
073		H-17	Jianping	Li	China	Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin in the treatment of Chinese adults with chronic HCV infection
074		H-18	leland	Yee	United States	Efficacy and safety of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B patients of Asian Ethnicity following 5-years of treatment
075		H-19	Riaz	Hussain	Pakistan	Efficacy of Pegylated Interferon-Alpha-2a in Chronic Hepatitis D Infected Patients. Experience from the Tertiary Care Hospital in Karachi.
076	s D	H-20	Andreas	Jekle	United States	Excellent preclinical characteristics of ALG-000184, a prodrug of the HBV capsid assembly modulator ALG-001075
077	and Hepatitis D	H-21	Chuqian	Zheng	China	HBx-mediated ETV4 facilitates hepatocellular carcinoma invasion and metastasis via up-regulating the Dishevelled-2
078	and He	H-22	Jin	Youn	South Korea	High Viral Suppression and Improved Safety Profile of Tenofovir Alafenamide Relative to Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients Treated for 5 Years
079	Hepatitis B a	H-23	Vadim	Bichko	United States	In Vitro and In Vivo Antiviral Properties of GST-HG141, a Novel Hepatitis B Virus Capsid Assembly Modulator in Clinical Development
080	epat	H-24	Natthaya	Chuaypen	Thailand	Molecular epidemiology and evidence of patient-to-patient transmission of hepatitis C virus within hemodialysis units
081	I	H-25	Sneha	Gupta	United States	Pharmacokinetics of VIR-2218, an RNAi therapeutic for the treatment of HBV infection, in healthy volunteers
082		H-26	Vikrant	Gohil	United States	Preclinical Efficacy and Pharmacokinetics of ALG-010133, an S-Antigen Transport-inhibiting Oligonucleotide Polymer (STOPS™) for the Treatment of Chronic Hepatitis B (CHB)
083	-	H-27	Bibigul	Ilyassova	Kazakhstan	Prevalence of hepatitis delta virus genotypes among patients with chronic viral hepatitis B with a Delta agent in Kazakhstan
084		H-28	Taeang	Arai	Japan	Real-world outcomes of sequential therapy with tenofovir alafenamide following long-term entecavir
085		H-29	Yuyong	Jiang	China	Retreatment of Hepatitis C Failed a NS5A-containing DAAs Regimen
086		H-30	Jin	Youn	South Korea	Safety and Efficacy of Tenofovir Alafenamide in Geriatric Patients with Chronic Hepatitis B: Experience from 4 Ongoing Phase 2 and Phase 3 Clinical Trials
087		H-31	Jeysen	Yogaratnam	United States	Safety and pharmacokinetics of single ascending doses of ALG- 000184, a Class II Capsid Assembly Modulator for the treatment of Chronic Hepatitis B, in healthy volunteers
088		H-33	Chung-Feng	Huang	Taiwan	Scaling up in-hospital HCV care cascade in a medical center in Taiwan
089		H-34	Grace Lai-Hung	Wong	Hong Kong	Secular trend of disease burden in patients with chronic viral hepatitis – a territory-wide study of 143,701 patients with data from HADCL in 2000-2018
090		H-35	You-Wen	Tan	China	Serum miRNA panel as potential biomarker for progression of chronic hepatitis B fibrosis

No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
091		H-36	Dong	Yan	China	Significance of switching from ETV to TAF for CHB patients with suboptimal response to ETV: A Retrospective Cohort Study
092		H-37	Erkin	Musabaev	Uzbekistan	Simplified test & treat protocols to eliminate HCV & HBV in Uzbekistan
093		H-38	Apichaya	Khlaiphuengsin	Thailand	Successful Direct-Acting Antiviral Therapy Improves Circulating Mucosal-Associated Invariant T Cells In Patients With Chronic Hcv Infection
094		H-39	Tanat	Yongpisarn	Thailand	Systematic Review with Meta-analysis: Non-invasive assessment of liver fibrosis for the prediction of liver-related outcomes in chronic viral hepatitis C patients
095		H-40	Lichang	Chen	China	The effectiveness of DAAs treatment in patients with chronic hepatitis C: A multicenter, prospective, observational, real-world study in East China
096		H-41	Ching-i	Huang	Taiwan	The Fibrosis Characters of Hepatitis C Patients in Community.
097		H-42	Maneerat	Chayanupatkul	Thailand	The role of hepatitis C virus core antigen in the determination of treatment response after direct acting anti-viral agents.
098		H-43	Alver	Prasetya	Indonesia	The Safety and Efficacy of Direct-Acting Antivirals in HCV and HCV/HIV Patients with Blood Coagulation Disorders: A Systematic Review
099		H-44	Riaz	Hussain	Pakistan	Treatment Outcomes Of Sofosbuvir And Velpatasvir In Chronic Hepatitis C Patients Undergoing Hemodialysis.
100		H-45	Guan Huei	Lee	Singapore	Evolution of full-length hepatitis B virus quasispecies in HBeAgnegative patients during spontaneous viral reactivation and remission
101		H-49	Dian	Utami	Indonesia	Mother To Child Hepatitis B Virus Transmission: Analysis Of Toll- Like Receptor 2 (Tlr2) Expression, Hbsag, Hbeag, Anti-Hbs, Anti- Hbc, And Hepatitis Virus Dna Identification
102	Hepatitis B and Hepatitis D	H-50	Shuyan	Chen	China	Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B
103		H-51	Natthaya	Chuaypen	Thailand	Characteristics of HCC patients with 'HBsAg-negative and HBcrAg- positive' profile undergoing TACE
104		H-52	Natthaya	Chuaypen	Thailand	Single Nucleotide Polymorphisms of TRAIL Receptor 1 are Linked to the Risk of Hepatitis B Virus-Related Hepatocellular Carcinoma
105		H-53	Natthaya	Chuaypen	Thailand	Serum HBcrAg levels are correlated with intrahepatic replication activity in patients with HBeAg-positive chronic hepatitis B
106		H-54	Natthaya	Chuaypen	Thailand	Serum sulfatase-2 as a novel diagnostic and prognostic marker of HBV-related hepatocellular carcinoma
107		H-55	Natthaya	Chuaypen	Thailand	Characterization of Serum HBV RNA Quantification in the Phases of Chronic Hepatitis B Infection
108		H-56	Xiaoyan	Fang	China	ALT flare predicts hepatocellular carcinoma among antiviral treated patients with chronic hepatitis B: a cross-country cohort study
109		H-57	Xun	Qi	China	Effect of Glycyrrhizin on fibrosis regression in chronic hepatitis B patients treated with Entecavir
110		H-59	Chao	Wu	China	Liver inflammation and fibrosis of HBeAg-negative patients in the gray zone
111		H-60	Chao	Wu	China	High probability of significant liver inflammation in Asian chronic hepatitis B patients with normal ALT and detectable HBV DNA in absence of liver fibrosis

No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
112		H-61	Li	Xiaoke	China	The Chinese herbal TiaoGanBuXuJieDu formula inhibits HBV replication and HBV-related hepatoma cell proliferation
113		H-62	Kefang	Yao	China	Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the gray zone
114	is D	H-63	Kefang	Yao	China	Evaluation of hepatitis B core antibody levels in predicting liver inflammation in HBeAg-negative chronic hepatitis B patients with normal alanine aminotransferase and detectable HBV DNA
115	and Hepatitis	H-64	Jin	Hong	United States	ALG-020572, a next generation antisense oligonucleotide (ASO) with bridged nucleic acid chemistry, has a significantly improved preclinical profile
116	l pue	H-65	Naranzul	Nyamsuren	Mongolia	Survey on Hepatitis B immunization coverage among nurses in Mongolia
117		H-66	Naranzul	Nyamsuren	Mongolia	Awareness of viral hepatitis and immunization against HBV among the Health care workers
118	Hepatitis B	H-67	Bibigul	Ilyassova	Kazakhstan	Distribution of hepatitis B virus genotypes and subtypes in the general population of Kazakhstan
119	He	H-68	Yeni	Kim	South Korea	Correlations between non-invasive biomarkers and fibrosis scores in chronic hepatitis B patients treated with tenofovir disoproxil fumarate and tenofovir alafenamide in Phase 3 clinical trials
120		H-69	Yeni	Kim	South Korea	Impact of pre-treatment plasma HBV DNA levels on the rate of ALT normalization during antiviral therapy with TAF or TDF for CHB
121		H-70	Yeni	Kim	South Korea	Coadministration without or with food on the 96-week efficacy and safety of tenofovir alafenamide in virally suppressed chronic HBV patients switched from tenofovir disoproxil fumarate
122		H-71	Yeni	Kim	South Korea	Phase 3 Study Comparing Switching from TDF to TAF with Continued TDF Treatment in Virologically-suppressed Patients with CHB: Final Week 96 Efficacy and Safety Results
123		H-72	Yeni	Kim	South Korea	Safety and Efficacy of 24 Weeks Treatment with Oral TLR8 Agonist, Selgantolimod, in Viremic Adult Patients with Chronic Hepatitis B: A Phase 2 Study
124		H-73	Yeni	Kim	South Korea	Safety and Efficacy of Switching to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients with Hepatic Impairment: Week 48 Results from Phase 2 Study
125		I-01	Mariz	Asoy	Philippines	Novel Case of Chronic Hepatitis B Reactivation in a COVID- Confirmed 78-year-old Male: A Case Report
126		I-02	Urbano	Sbarigia	Belgium	A Literature Review of the Epidemiological and Long-term Clinical Burden of Chronic Hepatitis B (CHB) Infection in Asia-Pacific
127		I-04	Jinsha Karukapad	Abduljaleel	India	Anti HBs Titers in Health Workers in a Tertiary Care Centre
128	tis C	I-06	Xueping	Huang	China	Changes of soluble programmed death factor-1 during antiviral therapy of chronic HBV infection and its predictive value for HBV-induced hepatocellular carcinoma
129	Hepatitis C	I-07	Hasmik	Ghazinyan	Armenia	Characteristics of the Oral Mucosa in Patients with ChronicViral Hepatitis B
130	Η̈́	I-08	Huey-ling	Chen	Taiwan	Comparable maternal viral load reduction in TAF or TDF-treated pregnant women for preventing maternal HBV transmission
131		I-09	Eric	Chan	United Kingdom	Content development of a new self-stigma patient-reported outcome instrument for chronic hepatitis B: A qualitative study in China
132		I-10	Dong	Ji	China	Cost savings of the PAGE-B score in reducing hepatocellular carcinoma (HCC) surveillance in Chinese with chronic hepatitis B (CHB)-related cirrhosis

No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
133		I-12	Peng	Chen	China	Effectiveness and safety of Tenofovir Alafenamide (TAF) in nucleoside analogue (NA) treatment naïve patients with chronic hepatitis B (CHB) in China
134		I-14	Hyun Woong	Lee	South Korea	Extremely rare risk of hepatocellular carcinoma after naturally and Nucleos(t)ide Analogue induced Hepatitis B Surface Antigen Seroclearance
135		I-15	Ming-Lung	Yu	Taiwan	Impact of Sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients - a large cohort study from the nationwide HCV Registry Program (TACR)
136		I-16	Dong	Ji	China	Kinetics of HBsAg and ALT decline in nucleos(t)ide analogue treated HBV subjects
137		I-18	Zhengxin	Li	China	Liver Stiffness Measurement Change May Predict the Regression and Progression of Liver Fibrosis in Chronic Hepatitis B Patients
138		I-19	Zhengxin	Li	China	Liver Stiffness Measurement Change May Predict the Regression and Progression of Liver Fibrosis in Chronic Hepatitis B Patients
139		I-20	Yeni	Kim	South Korea	Long term follow-up of safety and efficacy of sofosbuvir-based HCV DAAs in pediatric patients
140		I-21	Lajpat	Rai	Pakistan	Long-Term Renal Safety Of Tenofovir Disoproxil Fumarate In Chronic Hepatitis B Patients
141		I-22	Toshifumi	Tada	Japan	Real-world virological efficacy and safety of ledipasvir and sofosbuvir in patients with chronic hepatitis C virus genotype 2 infection in Japan: a multicenter study
142		I-23	Hery Djagat	Purnomo	Indonesia	Response to Antiviral Therapy of Naïve Chronic Hepatitis B Patients in Semarang, Indonesia : a real-case study
143	Hepatitis C	I-24	Yeni	Kim	South Korea	Risk of end-stage renal disease among hepatitis C patients with chronic kidney disease treated with and without sofosbuvir
144	Нер	I-25	Eiichi	Ogawa	Japan	Sequential Therapy with Tenofovir Alafenamide (TAF) in Patients with Chronic Hepatitis B (CHB): An Interim Analysis of an Ongoing Multinational Prospective Study
145		I-26	Yan	Liang	Hong Kong	Sodium-glucose co-transporter 2 inhibitors reduce hepatocellular carcinoma incidence in diabetic patients with chronic hepatitis B
146		I-29	Dong	Ji	China	Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viremia
147		I-30	Peng	Chen	China	Switching to Tenofovir Alafenamide (TAF) from Entecavir in Chinese chronic hepatitis B (CHB) patients The effects on HBsAg clearance, relapse and safety after tenofovir
148		I-31	Onuma	Sattayalertyanyong	Thailand	and entecavir cessation in non-cirrhotic chronic hepatitis B, HBeAg negative patients
149		I-32	Agil Noviar	Alvirosa	Indonesia	The Efficacy and Safety of a Novel Oral TLR7 Agonist Vesatolimod (GS-9620) in Chronic Hepatitis B Patients: A Systematic Review
150		I-33	Ying	Han	China	The incidence of hepatocellular carcinoma in patients with hepatitis B cirrhosis during long-term antiviral therapy: A real world cohort study
151		I-34	Gireesh	G N	India	To study the prevalence of occult HBV infection in hematological cancer patients on & before cancer chemotherapy
152		I-35	Hafiz	Haris	Pakistan	Transient Elastography In Chronic Hepatitis B (Chb) Patients
153		I-36	Chun Han	Cheng	Taiwan	The impact of antiviral treatment with direct-acting antiviral agents on insulin resistance in chronic hepatitis C patients
154		I-37	Nyein Mon	Yu	Myanmar	Hepatitis C Genotype 3 subtypes and Y93H mutation in single center experience in Myanmar

No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
155		J-01	Vinod	Gowda K H	India	" Stock And Glove Hepatocellular Carcinoma " - A Rare Case Of Anti-Hu Antibody Positive Peripheral Neuropathy Secondary To Hepatocellular Carcinoma.
156		J-02	Osamu	Tanaka	Japan	99m-Technetium Galactosyl Human Serum Albumin Scanning to Evaluate Liver Function After Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Case Report
157		J-03	Kittipitch	Bannangkoon	Thailand	ABO Blood Group Differential on the Survival in Hepatocellular Carcinoma Patient Treated with Chemoembolization
158		J-04	Usama	Abdelkader	Egypt	Are vitamin D receptor polymorphisms associated with a risk of hepatocellular carcinoma in hepatitis C related liver cirrhosis?
159		J-05	Ji-Min	Zhu	China	Bismuth-based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy against Hepatocellular Carcinoma
160	_	J-06	Thiyaphat	Laohawetwanit	Thailand	Combined hepatocellular-cholangiocarcinoma and its mimickers: diagnostic pitfalls in surgical pathology Comparative long-term outcomes of surgical treatment for
161		J-07	Jai Young	Cho	South Korea	hepatocellular carcinoma in patients with non-alcoholic fatty liver disease versus patients with hepatitis B
162		J-09	Ulziisaikhan	Banzragch	Mongolia	Correlation between serum alpha-fetoprotein level and tumor size in hepatocellular carcinoma patients from the national cancer center in Mongolia
163	ë	J-10	Grace Lai-Hung	Wong	Hong Kong	Deep learning of CT images in patients with chronic viral hepatitis – a territory-wide study with data from HADCL from year 2000 to 2017
164	oplas	J-11	Thodsawit	Tiyarattanachai	Thailand	Development and validation of artificial intelligence to detect and diagnose liver lesions from ultrasound images
165	ě	J-12	Yi-sheng	Liu	Taiwan	Drug-loadable T-ACE Bead for Hepatoma Embolization Therapy
166	<u> </u>	J-13	Tetsuhiro	Chiba	Japan	FGF19/FGFR4 signaling in hepatocellular carcinoma
167	Hepatobiliary Neoplasia	J-14	Hasmik	Ghazinyan	Armenia	Hepatocellular carcinoma emergence in Armenia: Outcome of multiple risk factors for the period January 2019 to March 2020, Nork Clinical Hospital of Infectious Diseases
168	Чера	J-15	Sreedhara	Chaluvashetty	India	Image-guided locoregional therapies in the management of HCC
169		J-16	Eiichiro	Suzuki	Japan	Impact of liver cirrhosis in patients with intrahepatic cholangiocarcinoma receiving systemic chemotherapy: a subgroup analysis of the JCOG1113 randomized phase III trial
170		J-17	Kazufumi	Kobayashi	Japan	Impact of multi molecular target agent therapy in advanced hepatocellular carcinoma
171		J-18	Thiyaphat	Laohawetwanit	Thailand	Interpretation pitfalls in immunohistochemistry of primary liver carcinoma: a retrospective analysis of liver biopsy specimens
172	_	J-19	Robert	O'Neill	Australia	Massive hepatomegaly and abdominal pain – An unexpected presentation of primary choroidal melanoma
173	_	J-20	Sangdao	Boonkaya	Thailand	Outcomes of patients with advanced stage hepatocellular carcinoma (HCC) receiving different treatment modalities: Realworld data
174		J-21	Keisuke	Koroki	Japan	Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
175		J-22	I-ting	Liu	Taiwan	Predict Early Recurrence of Hepatocellular Carcinoma Using Multi- dimensional Artificial Intelligence Analysis of Liver Fibrosis
176	_	J-23	Thomas	Yau	Hong Kong	Prospective validation of the Hong Kong Liver Cancer Classification (HKLC): Preliminary Result
177	-	J-24	Takashi	lizumi	Japan	Proton beam therapy for hepatocellular carcinoma with bile duct invasion
178		J-25	Danny	Wang	Hong Kong	Real World Experience of Management of Unresectable Hepatocellular Carcinoma
179		J-26	Tongluk	Teerasarntipan	Thailand	Risk factors of cholangiocarcinoma in non-endemic area of liver fluke infection
180		J-27	Gireesh	G N	India	Serum cytokeratin as a biomarker in assessing the severity of patients with liver cirrhosis with Hepatocellular carcinoma

No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
181		J-28	Jin-shui	Pan	China	Socioeconomic development status and the global burden of common cancers of the gastrointestinal tract including liver cancer, 1990–2017
182		J-29	Jingwen	Zou	China	Surgical Strategies for Hepatocellular Carcinoma Located in Left Lateral Lobe: A Prognostic Nomogram Study
183		J-31	Engin	ALTINTAS	Turkey	The Evaluation Of The Role Of Liver Stiffness Measurement In Predicting Hepatocellular Carcinoma In Chronic Hepatitis C Patient
184		J-32	Mahmoud	Elkadeem	Egypt	The Potential Role of Dickkopf-1 and β -catenin as Biomarkers for the Diagnosis of Hepatocellular Carcinoma Patients
185		J-33	Ashok	Raj	New Zealand	The prevalence of palliative presentation for HCC over 10 years in a Maori, Pasifika and Asian cohort
186		J-34	Jingwen	Zou	China	Transarterial Infusion Chemotherapy with FOLFOX Regimen Could Be An Effective and Safe Treatment for Unresectable Intrahepatic Cholangiocarcinoma
187	asia	J-36	thanikan	Sukaram	Thailand	Volatile organic compounds as potential biomarkers for diagnosis of hepatocellular carcinoma (HCC)
188	Neopl	J-37	Jaejun	Lee	South Korea	Comparison of Lenvatinib versus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma.
189	Hepatobiliary Neoplasia	J-37	Margaret LP	Teng	Singapore	Complication Rates, Overall And Recurrence-Free Survival After Surgical Resection With Curative Intent For Hepatocellular Carcinoma: A Meta-Analysis Of 110 Studies And 82,392 Patients
190	Hepat	J-38	Heechul	Nam	South Korea	A multi-center study to investigate the role of sarcopenia as a prognostic factor in patients with hepatocellular carcinoma treated by trans-arterial radioembolization
191		J-39	Qing	Li	China	HIF- 1α -induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation
192		J-40	Qing	Li	China	Kinesin family member 15 promotes cancer stem cell phenotype and malignancy via reactive oxygen species imbalance in hepatocellular carcinoma
193		J-41	Minseok Albert	Kim	South Korea	Yttrium-90 Radioembolization Is Associated with Better Overall Survival in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study
194		J-42	Yoonseok	Lee	South Korea	Development of hand foot skin reaction is associated with good prognosis for HCC patients treated with Sorafenib; A prospective cohort study
195		J-43	Qing	Li	China	Thymidine kinase 1 drives the malignancy and immunosuppression by regulating the PRMT1/YAP axis in Hepatocellular carcinoma
196		Q-15	Erlangga	Arifin	Indonesia	The Efficacy of Lapatinib as a Safer Therapeutic Agent in Hepatocellular Carcinoma Patients: A Systematic Review
197	gery	K-01	Andrea	Benedetti Cacciaguerra	Italy	Clinical outcome of laparoscopic versus open major liver resection in Cirrhotic patients. A Propensity Score Matched Analysis
198	y Sur	K-02	Hendra	Koncoro	Indonesia	Multiple Gallstones And Bile Duct Stones In Chronic Myelogenous Leukemia
199	Hepatobiliary Surgery	K-03	Saif	Ullah	China	Pure NOTES trans-rectal gallbladder preserving cholecystolithotomy: an alternative option for the treatment of symptomatic gallstones
200	Нера	K-04	Jiangdong	Qiu	China	Somatostatin prevents clinically relevant pancreatic fistula in intermediate risk patients after pancreaticoduodenectomy (SPEED): a multi-center, randomized, controlled study
201		L-01	Stephanie	Johanes	Indonesia	Alpha-Methyldopa Induced Hepatotoxicity In Women With Hypertensive Disorders Of Pregnancy: A Systematic Review Of Case Reports

No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
202		L-02	Lajpat	Rai	Pakistan	Covid 19 Associated Liver Injury: Clinical Manifestations, Challenges And Outcome: A Real Life Experience From Pakistan
203		L-03	Meenal	Patwardhan	United States	Drug- Induced Liver Injury in the Elderly – Do We Know What We Don't Know?
204		L-04	Rivaldi	Ruby	Indonesia	Hepatoprotectants Efficacy Against Anti-Tuberculosis Drug- Induced Liver Injury: A Systematic Review Of Randomized Controlled Trial
205	Hepatotoxicity	L-05	Xi	Chen	China	Preliminary Screening For The Hepatotoxic Substances From Tripterygium Wilfordii
206	toto;	L-06	Stephanie	Johanes	Indonesia	Remdesivir Associated Acute Liver Injury In Covid-19 Patients: A Case Based Systematic Review
207	Чера	L-07	Abeer	Altaf	Pakistan	Severity Of Covid-19 Is Associated With Liver Injury In Patients Without Pre-Existing Liver Disease
208	_	L-08	Mithun Harold	Thomas	India	Statin Related Drug Induced Liver Injury: A Case Series
209		L-09	Syed	Ali	Pakistan	The Etiology Of Drug Induced Liver Injury In Patients Presenting To A Tertiary Care Hospital, Karachi.
210		L-10	Hyun	Yang	South Korea	Intrahepatic infiltration of activated CD8+ T cells and macrophages is associated with the severity of liver injury in drug-induced liver injury: implications in steroid therapy
211		L-11	Parimita	Barua	India	To study LFT abnormality in patients with ischemic hepatitis and congestive hepatopathy and 7 days predictor of mortality.
212		L-12	Abhasnee	Sobhonslidsuk	Thailand	Drug-induced liver injury registry and the study of factors associated with its clinical course: a multicenter study
213	S	M-01	sai	Harish	India	Association between intra hepatic cholestasis of pregnancy & fatty liver : Single centre observational study
214	tic and Disease	M-02	Ying	Han	China	Establishing a non-invasive diagnosis model of liver cirrhosis in patients with primary biliary cholangitis based on the liver disease research database
215	lesta Liver	M-03	Jaspreet	Kaur	India	Seronegative Primary Biliary Cholangitis In A Middle Aged Male : A Rare Entity
216	Human Cholestatic and Autoimmune Liver Diseases	M-04	Alver	Prasetya	Indonesia	The Potential of Soluble Programmed Cell Death Protein-1 (sPD-1) and Anti-PD-1 as Serological Markers of Autoimmune Hepatitis: A Systematic Review
217	Hun	M-05	Kim	Vaiphei	India	Two autopsy cases with rare aetiologies for massive hepatomegaly in middle aged females
218	∢	M-06	Chunpan	Zhang	China	Double negative T cells therapy alone or in combination with oral UDCA alleviates primary biliary cholangitis in mice
219	Inflammation and Immunobiology	N-01	Arnab	Dey	India	A Prospective Case Control Study Of Liver Dysfunction In Hyperthyroidism With Special Reference To Portal Venous Flow And Fibrosis Assesement And Its Reversal Following Treatment
220	nuno	N-02	Bontha	Vineesha	India	Clinico-epidemiological profile of liver abscess patients admitted in a tertiary center in south india.
221	<u>ii</u> p	N-03	Termpong	Dumrisilp	Thailand	Impact of overweight and obesity on live attenuated hepatitis A vaccine response in children and young adult
222	าก ลก	N-04	ASTUSHI	NAKAMURA	Japan	Impact of Systemic Inflammation on Liver Function as Assessed by ALBI Grade
223	nmatic	N-05	Pil Soo	Sung	South Korea	Expression analysis by Nanostring nCounter system in non- alcoholic steatohepatitis identifies activated macrophages as key mediators of inflammation
224	Inflar	N-06	Pil Soo	Sung	South Korea	Inflammation-induced, IgA (+) PD-L1-high tumor-associated macrophages are the main targets of immune checkpoint inhibitors in hepatocellular carcinoma

No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
225		0-01	Olga	Tarasova	Russian Federation	EPR-TSA method for the diagnosis of liver fibrosis
226	Liver Fibrogenesis and Non- Parenchymal Cell Biology	O-02	Xudong	Hu	China	Fuzhenghuayu recipe alleviates DMN-induced mice liver fibrosis through regulating recruitment and phenotype polarization of Bone marrow-derived macrophages
227	iver Fibrogenesis and Nor Parenchymal Cell Biology	O-03	Jinsha Karukapad	Abduljaleel	India	Gamma Glutamyl Transpeptidase to Platelet Ratio – To Assess Liver Fibrosis in Chronic Liver Disease
228	gene: mal C	O-04	Xingshun	Qi	China	Liver Biochemical Abnormality and In-hospital Outcome in COVID- 19 Patients with Liver Cirrhosis
229	Fibro enchy	O-05	Xiya	Lu	China	miR-30d Alleviates Liver Fibrosis through Inhibiting Hepatic Stellate Cell Activation
230	Liver Par	O-06	Ryota	Masuzaki	Japan	Small surgical incisions in the liver cause fibrotic response in adult and neonatal mice.
231		O-07	Gireesh	G N	India	To evaluate the liver fibrosis by transient elastography in IBD patients on treatment with Azathioprine
232	<u>~</u>	P-01	Deepak	Deepak	India	Analgesic Efficacy of ultrasound –guided Erector Spinae plane Block for percutaneous biliary drainage- A randomized control trial
233	Surge	P-02	Smita	Parakh	India	Comparison of safety and efficacy of early drain removal vs conventional drain removal in living donor liver transplant (LDLT)
234	Liver	P-04	Ken	Liu	Australia	Impact of intensive care unit discharge delay on outcomes after liver transplantation
235	Liver Transplantation and Liver Surgery	P-05	Smita	Parakh	India	Is Abdominal Tuberculosis (TB) found at the time of Liver Transplantation a contraindication to Living Donor Liver Transplantation (LDLT)
236	antatio	P-06	Stephanie	Johanes	Indonesia	Low Birth Weight And Preterm Delivery In Pregnancies Following A Liver Transplant: A Systematic Review Of Retrospective Cohort Studies
237	ranspl	P-07	Maxat	Doskhanov	Kazakhstan	The first experience of magnetic compression anastomosis correction of biliary strictures after liver transplantation from a living donor
238	Liver T	P-08	Stephanie	Johanes	Indonesia	The Role Of Qt Prolongation And Nt-Probnp To Predict Mortality In Liver Transplant Patient: A Systematic Review And Meta Analysis
239		P-09	Jalpa	Devi	Pakistan	Trends in Etiology of Chronic Liver Disease referred for Liver Transplant evaluation in Pakistan 2020
240		Q-01	Hozefa	Runderawala	India	"The triglyceride and glucose index (TyG) as screening biomarker to identify nonalcoholic fatty liver disease (NAFLD)"
241		Q-02	Hozefa	Runderawala	India	"The triglyceride and glucose index (TyG) as screening biomarker to identify nonalcoholic fatty liver disease (NAFLD)"
242	I	Q-03	Jee-Fu	Huang	Taiwan	A Double-Blind, Randomized, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Pioglitazone in Taiwanese Patients with Nonalcoholic Steatohepatitis
243	NAFLD and NASH	Q-04	Umida	Usmanova	Uzbekistan	A New Method For Early Diagnostics Of Obesity In Non-Alcoholic Fatty Liver Disease
244	and	Q-05	Bhargav	VY	India	Age and gender differences in "cluster" components of metabolic syndrome in Non-Alcoholic Fatty Liver Disease
245		Q-06	Bhargav	VY	India	Age and Gender variations of FIB 4 score in fatty liver.
246	NAF	Q-07	Jenny	Chu	Hong Kong	Association between chronic hepatitis B and human immunodeficiency virus infection with hepatic steatosis and fibrosis by non-invasive assessment
247		Q-08	Hsiu Ping	Lin	Taiwan	BioFibroScore®: a new non-invasive method for diagnosing hepatic fibrosis in NAFLD and NASH
248		Q-09	Ajay	Duseja	India	Changing clinicopathological profile of nonalcoholic fatty liver disease in India - Interim results of the ICON-D (Indian Consortium on NAFLD) Study

No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
249		Q-10	Ajay	Duseja	India	Clinical outcomes in a real-world cohort of patients with non- alcoholic fatty liver disease in South Asia
250		Q-12	Souveek	Mitra	India	Contribution of "multiple hit " to NAFLD pathology differ in obese and non obese population
251		Q-13	David	Thomas	India	Does Nafld Prove To Be An Independent Risk Factor For Cad Patients ?—A Single Centre Case-Control Study.
252		Q-14	Satyendra K	Tyagi	India	Efficacy of saroglitazar in non- alcoholic fatty liver disease using real world clinically relevant non- invasive parameters
253		Q-15	Erlangga	Arifin	Indonesia	Empagliflozin Effect of Reducing Liver Fat in NAFLD Patients with DM type 2: A Systematic Review of a Potent Therapeutic Agent
254		Q-16	David	Thomas	India	FAT Score : A novel predictive score to differentiate Non-alcoholic steatohepatitis (NASH) from Simple steatosis
255		Q-17	Nazeer	Ahmed	Pakistan	Fibroscan findings in patients with fatty liver on ultrasonography.
256		Q-19	Elijah	Weber	United States	Japanese subjects have moderately higher plasma exposures of the acetyl CoA carboxylase (ACC) inhibitor firsocostat (FIR) than Caucasian subjects
257		Q-20	Elijah	Weber	United States	Lack of Clinically Meaningful Differences in Pharmacokinetics and Pharmacodynamics of the FXR agonist Cilofexor in Japanese and Caucasian Participants
258		Q-21	Mahmoud	Elkadeem	Egypt	Measurement of Liver Stiffness by Transient Elastography versus Other Non-Invasive Markers for assessment of fibrosis in Non- Alcoholic Fatty Liver Disease
259	SH	Q-22	Danny	Wang	Hong Kong	NAFLD is a risk factor for venous thromboembolism in COVID-19
260	N b	Q-23	Olga	Tarasova	Russian Federation	New Possibilities Of Saliva Investigation For Diagnosis Of Steatohepatitis
261	NAFLD and NASH	Q-24	Nidhin	R	India	Non invasive assessment of cardiovascular risk using carotid intima media thickness in patients with Inflammatory bowel disease –Does Non alcoholic Fatty liver disease add on to the risk?
262		Q-26	Vikranth	Chunduri venkata viswa	India	Prevalence of non-alcoholic fatty liver disease in adolescent boys and its association with obesity and lifestyle factors in rural TamilNadu
263		Q-27	Swetha	Sattanathan	India	Real world evidence of Saroglitazar in Nonalcoholic Fatty Liver Disease patients: A prospective 6-month follow-up study
264		Q-28	Su	Lin	China	Risk of HCC in HBV concomitant with liver steatosis: the comparison between NAFLD and MAFLD definition in a large biopsy cohort
265		Q-29	Prooksa	Ananchuensook	Thailand	Role of liver stiffness value in predicting of hepatocellular carcinoma and liver related complications among advanced fibrosis NAFLD patients
266		Q-30	Gregor	Weber	United States	Safety and efficacy of combination therapies including semaglutide, cilofexor, and firsocostat in patients with NASH
267		Q-31	Xinrong	Zhang	Hong Kong	Screening Colonoscopy and Colorectal Cancer Incidence in Patients with Non-Alcoholic Fatty Liver Disease: A Retrospective Cohort Study
268		Q-32	Grit	Andersen	Germany	Semaglutide treatment in subjects with NAFLD: Effects assessed by magnetic resonance elastography and magnetic resonance imaging proton density fat fraction
269		Q-33	Kotchakon	Maipang	Thailand	Significant Liver Fibrosis is Associated with Increased Risk of Advanced Adenoma in Average-Risk Population with Metabolic Associated Fatty Liver Disease
270		Q-34	Sherief	Abd-Elsalam	Egypt	The Effect of HCV Eradication after Direct Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study
271		Q-35	Wei-Yu	Kao	Taiwan	The plasma and liver triglyceride subclass of nonalcoholic steatohepatitis and fibrosis in morbidly obese patients

No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
272		Q-36	Jenny	Norlin	Denmark	Triple combination therapy of GLP-1 receptor agonist semaglutide with an FXR agonist and ACC inhibitor reverses non-alcoholic steatohepatitis (NASH) in diet-induced and biopsy-confirmed mice
273		Q-37	Soo Min	Bang	South Korea	Diagnosis of nonalcoholic steatohepatitis with MR-based nonalcoholic steatohepatitis score
274		Q-38	Soo Min	Bang	South Korea	Serum miRNA as a useful diagnostic biomarker for non-alcoholic steatohepatitis and a predictor for disease progression in patients with non-alcoholic fatty liver disease
275		Q-39	Li	Changying	China	The proportions and functions of CD4-CD8- double negative T cells during non-alcoholic fatty liver disease development
276		Q-40	Rui	Huang	China	Risk of severe illness of COVID-19 patients with NAFLD and increased NAFLD fibrosis scores
277		Q-41	Thaninee	Prasoppokakorn	Thailand	Validation Model of FIB-8 Score to Predict Significant Fibrosis Among Patients with Non-alcoholic Fatty Liver Disease The impurous plates release of moletonia on distributed
278		Q-42	Wang	Yaning	China	The immunoregulatory roles of melatonin on diets-induced nonalcoholic steatohepatitis
279		Q-43	Zijian	Zhang	China	Development and validation of a robust predictor for the carcinogenesis potential of non-alcoholic steatohepatitis patients: NASH-related Carcinogenesis Score (The NASH-C Score)
280		R-01	Heather	Sevinsky	United States	AB-729, a GalNAc-siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection
281	ıtitis	R-02	Jin	Youn	South Korea	Characterization of Serologic Responses Following ALT Flares in >3000 CHB Patients Pooled from 5 Clinical Trials
282	Чера	R-03	Wenyu	Wu	China	Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China
283	Other Viral Hepatitis	R-04	Damodar	Krishnan	India	Clinical profile and factors influencing mortality of patients diagnosed with acute Hepatitis E in a tertiary center in South India
284	ther	R-06	Waleerat	Sawatdee	Thailand	Comparison of the efficacy and safety of entecavir tablet and solution in patients with chronic hepatitis B
285	O	R-08	Wenyu	Wu	China	Fibrinogen-like protein 2 promotes fulminant hepatitis by inducing neutrophil activation and neutrophil extracellular traps formation
286		R-09	Masood Muhami	Karim	Pakistan	Frequency of Hepatitis E in Pregnant Women With acute Hepatitis.
287		R-10	Young-Suk	Lim	South Korea	Impact of Expanding Antiviral Treatment Criteria at a Population Level in the Republic of Korea: A modeling analysis
288		R-12	Narisara	Tribuddharat	Thailand	Incidence and characteristic of Dengue hemorrhagic fever with severe hepatitis
289		R-13	Tatsuo	Kanda	Japan	Inhibitory effects of zinc chloride on hepatitis A virus replication through the cytokines in hepatocytes
290		R-15	Sanjay	Chandnani	India	Prevalence of deranged Liver function tests in COVID-19 patients and their outcome among Indian population- An interim analysis
291		R-18	Hideo	Yoshida	Japan	SARS-cov2 infection and liver dysfunction
292		R-19	Tatsuo	Kanda	Japan	Screening for inhibitors of hepatitis A virus internal ribosomal entry site and HAV replication
293		R-20	Tauseef	Ahmad	China	Seroprevalence of Hepatitis E infection among slaughter workers in China
294		R-21	Rattanaporn	Kiatbumrung	Thailand	The Association of PNPLA3, COX-2 and DHCR7 Polymorphisms with Advanced Liver Fibrosis in Patients with HCV Mono- Infection and HCV/HIV Co-Infection
295		R-22	Mindie	Nguyen	United States	Treatment outcome with DAAs in a multinational cohort of 11,099 hepatitis C (CHC) patients with genotypes 1, 2, 3, 4 and 6: A REAL-C study

No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
296		R-23	Lung-Yi	Mak	Hong Kong	Role of serum M2BPGi levels in predicting persistence of advanced fibrosis in chronic hepatitis B virus infection
297	Other Vira Hepatitis	R-24	Jee-Fu	Huang	Taiwan	Significant amelioration of hepatitis C virus infection in a hyper- endemic area: Longitudinal evidence from the COMPACT Study in Taiwan
298	Oth	R-25	Lung-Yi	Mak	Hong Kong	Regression of liver fibrosis after HBsAg loss: a prospective matched case-control evaluation using transient elastography and serum Enhanced Liver Fibrosis (ELF) test
299		S-01	Patcharin	Amornvipas	Thailand	A Thai Girl fever with hepatosplenomegaly and liver cyst
300		S-02	Piyush	Upadhyay	India	Hyponatremia in Childhood Chronic Liver Disease: Prevalence, Predictors and Impact on Outcome.
301		S-03	Jayendra	Seetharaman	India	Is Exchangeable Copper A Promising Diagnostic And Prognostic Tool In Hepatic Wilson'S Disease?
302	Pediatric Hepatology	S-04	Priti	Vijay	India	Newer markers and Calculated Acute Kidney Injury score: better diagnostic accuracy for acute kidney injury (AKI) in children with chronic Liver Disease (CLD) and portal hypertension (PHTN)
303	ric Hep	S-05	Piyush	Upadhyay	India	Non-Invasive Portal Hypertensive Indices And Portal Hemodynamics On Doppler For Prediction Of Clinically Significant Varices In Children With Chronic Liver Disease.
304	ediati	S-06	Bony	George	India	Normative data of Liver Stiffness Measurement (LSM) by Transient Elastography in healthy Indian children
305	Pe	S-07	Chatmanee	Lertudomphonwanit	Thailand	Prevalence And Long-Term Outcome Of De Novo Hepatitis B Infection In Pediatric Liver Transplant Recipients
306		S-08	Chatmanee	Lertudomphonwanit	Thailand	Low Psoas Muscle Index As An Unfavorable Factor In Children With End-Stage Liver Disease Undergoing Liver Transplantation
307		S-09	Arun	Prabhakaran	India	A novel predictor for fibrosis in Pediatric Non-Alcoholic Fatty Liver Disease
308	sis	T-01	Vishav Dev Singh	Dadwal	India	Spectrum And Outcome Of Infections In Cirrhotic Patients In A Tertiary Liver Centre
309	Portal Hypertension and Other Complications of Cirrhosis	T-02	Ellaine	Wei-munji	Philippines	A Comparative Study on the Diagnostic Accuracy of Non-Invasive Scoring Tests in detecting Esophageal Varices in patients with Liver Cirrhosis – A Retrospective Study
310	ations	T-03	Yu	Tian	China	A status survey of albumin infusion and its relationship with prognosis in cirrhotic patients with ascites in China
311	Complica	T-04	Sandheep	Janardhanan	India	A Study Of Serum Cystatin C Levels As A Diagnostic Marker Of Early Renal Dysfunction In Critically III Cirrhotic Patients Admitted To Intensive Care Unit (ICU)
312	ther	T-05	Sakkarin	Chirapongsathorn	Thailand	Acute-on-Chronic Liver Failure: Epidemiology, Prognosis and Outcome in Thai population, multicenter study (ACLF-TM)
313	o pu	T-06	Xingshun	Qi	China	Adherence to Non-Selective Beta Blockers in Cirrhotic Patients with Esophageal Varices
314	ion a	T-07	Adinda	Rahadini	Indonesia	Anticoagulant Therapy for Cirrhosis-related Portal Vein Thrombosis: A Meta-Analysis
315	tens	T-08	Swetha	Sattanathan	India	Changes in liver and spleen stiffness following Endoscopic variceal ligation as predictors of variceal eradication
316	Нурег	T-09	Bony	George	India	CHIBA score , A novel model for predicting 3 month mortality in Decompensated Liver Disease (DCLD
317	ortalli	T-10	Veera Abhinav	Chinta	India	Clinical And Endoscopic Profile Of Patient Presenting With Variceal Upper Gi Bleed In Cirrhotics At Srmc-Chennai
318	ΡC	T-11	Rajkumar Pranna	Wadhwa	India	Clinical profile of Acute Variceal Haemorrhage: a single-center study

T.12 Veera Abhinav Chinta India Clinical Profile of Patients With Gastric Variceal Bleed And Outcomes Of Cyanoacrylate Glise Injection-Single Center Experience	No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
T-13 Peng Zhu China stiffness measurement for pradicting esophageal-gastric varies in patients with cirricols	319		T-12	Veera Abhinav	Chinta	India	Outcomes Of Cyanoacrylate Glue Injection- Single Center
T-14 Rivaldi Ruby Indonesia As Portal Pressure Reduction Therapy In Clirhody Calentics With portal Hyperension. A Systematic Review Of Randomized Controlled Trial Comparing Four Prognostic Scores in Predicting Short-term Mortality of Patients with Acute-On-Chronic Liver Failure (ACLF)	320		T-13	Peng	Zhu	China	stiffness measurement for predicting esophageal-gastric varices in
T-15 Kessarin Thanapirom Thailand Mortality of Patients with Acute-On-Chronic Liver Failure: a multicenter study	321		T-14	Rivaldi	Ruby	Indonesia	As Portal Pressure Reduction Therapy In Cirrhotic Patients With Portal Hypertension: A Systematic Review Of Randomized
1923 1932 1932 1932 1932 1932 1932 1933	322		T-15	Kessarin	Thanapirom	Thailand	Mortality of Patients with Acute-On-Chronic Liver Failure: a multi-
T-25 Xingshun Qi China Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis No association of homocysteine, anticardiolipin antibody, and anti- β2 glycoprotein I antibody with portal venous system thrombosis in liver cirrhosis T-27 Sherief Abd-Ælsalam Egypt Prophylaxis of Spontaneous Bacterial Peritonitis: A Randomized Trial T-28 Jeong Han Kim South Korea One month and three month readmission rates in cirrhotic patients were not changed during past seven years Outcomes of early versus delayed endoscopy in cirrhotic patients with acute variceal bleeding: A systematic review and meta- analysis T-31 Xingshun Qi China Portal venous system thrombosis after bariatric surgery: A systematic review and meta-analysis T-32 Masood Muhamy Karim Pakistan Portosystemic Encephalopathy (PSE) recurrence in cirrhotic	323	rhosis	T-16	Napapong	Nitiwaranggoon	Thailand	Organ Failures of Cirrhotic Patients Hospitalized with an Acute Decompensation with and without Acute-on-Chronic Liver Failure
T-25 Xingshun Qi China Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis No association of homocysteine, anticardiolipin antibody, and anti-β2 glycoprotein I antibody with portal venous system thrombosis in liver cirrhosis T-27 Sherief Abd-Elsalam Egypt Prophylaxis of Spontaneous Bacterial Peritonitis: A Randomized Trial T-28 Jeong Han Kim South Korea One month and three month readmission rates in cirrhotic patients were not changed during past seven years Outcomes of early versus delayed endoscopy in cirrhotic patients with acute variceal bleeding: A systematic review and metaanalysis T-31 Xingshun Qi China Portal venous system thrombosis after bariatric surgery: A systematic review and meta-analysis T-32 Masood Muhamm Karim Pakistan Portosystemic Encephalopathy (PSE) recurrence in cirrhotic	324	of Cir	T-17	Mithun Harold	Thomas	India	
T-25 Xingshun Qi China Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis No association of homocysteine, anticardiolipin antibody, and anti-β2 glycoprotein I antibody with portal venous system thrombosis in liver cirrhosis T-27 Sherief Abd-Elsalam Egypt Prophylaxis of Spontaneous Bacterial Peritonitis: A Randomized Trial T-28 Jeong Han Kim South Korea One month and three month readmission rates in cirrhotic patients were not changed during past seven years Outcomes of early versus delayed endoscopy in cirrhotic patients with acute variceal bleeding: A systematic review and metaanalysis T-31 Xingshun Qi China Portal venous system thrombosis after bariatric surgery: A systematic review and meta-analysis T-32 Masood Muhamm Karim Pakistan Portosystemic Encephalopathy (PSE) recurrence in cirrhotic	325	ons (T-18	Gireesh	G N	India	
T-25 Xingshun Qi China Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis No association of homocysteine, anticardiolipin antibody, and anti-β2 glycoprotein I antibody with portal venous system thrombosis in liver cirrhosis T-27 Sherief Abd-Elsalam Egypt Prophylaxis of Spontaneous Bacterial Peritonitis: A Randomized Trial T-28 Jeong Han Kim South Korea One month and three month readmission rates in cirrhotic patients were not changed during past seven years Outcomes of early versus delayed endoscopy in cirrhotic patients with acute variceal bleeding: A systematic review and metaanalysis T-31 Xingshun Qi China Portal venous system thrombosis after bariatric surgery: A systematic review and meta-analysis T-32 Masood Muhamm Karim Pakistan Portosystemic Encephalopathy (PSE) recurrence in cirrhotic	326	olicati	T-19	Ksheetij	Kothari	India	
T-25 Xingshun Qi China Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis No association of homocysteine, anticardiolipin antibody, and anti-β2 glycoprotein I antibody with portal venous system thrombosis in liver cirrhosis T-27 Sherief Abd-Elsalam Egypt Prophylaxis of Spontaneous Bacterial Peritonitis: A Randomized Trial T-28 Jeong Han Kim South Korea One month and three month readmission rates in cirrhotic patients were not changed during past seven years Outcomes of early versus delayed endoscopy in cirrhotic patients with acute variceal bleeding: A systematic review and metaanalysis T-31 Xingshun Qi China Portal venous system thrombosis after bariatric surgery: A systematic review and meta-analysis T-32 Masood Muhamm Karim Pakistan Portosystemic Encephalopathy (PSE) recurrence in cirrhotic	327	Comp	T-20	Koki	Nagai	Japan	
T-25 Xingshun Qi China Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis No association of homocysteine, anticardiolipin antibody, and anti-β2 glycoprotein I antibody with portal venous system thrombosis in liver cirrhosis T-27 Sherief Abd-Elsalam Egypt Prophylaxis of Spontaneous Bacterial Peritonitis: A Randomized Trial T-28 Jeong Han Kim South Korea One month and three month readmission rates in cirrhotic patients were not changed during past seven years Outcomes of early versus delayed endoscopy in cirrhotic patients with acute variceal bleeding: A systematic review and metaanalysis T-31 Xingshun Qi China Portal venous system thrombosis after bariatric surgery: A systematic review and meta-analysis T-32 Masood Muhamm Karim Pakistan Portosystemic Encephalopathy (PSE) recurrence in cirrhotic	328	d Other (T-21	Jalpa	Devi	Pakistan	in Acute Variceal Bleeding patients? South East Asia Experience.
T-25 Xingshun Qi China Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis No association of homocysteine, anticardiolipin antibody, and anti-β2 glycoprotein I antibody with portal venous system thrombosis in liver cirrhosis T-27 Sherief Abd-Elsalam Egypt Prophylaxis of Spontaneous Bacterial Peritonitis: A Randomized Trial T-28 Jeong Han Kim South Korea One month and three month readmission rates in cirrhotic patients were not changed during past seven years Outcomes of early versus delayed endoscopy in cirrhotic patients with acute variceal bleeding: A systematic review and metaanalysis T-31 Xingshun Qi China Portal venous system thrombosis after bariatric surgery: A systematic review and meta-analysis T-32 Masood Muhamm Karim Pakistan Portosystemic Encephalopathy (PSE) recurrence in cirrhotic	329	nsion an	T-23	Wasuwit	Wanchaitanawong	Thailand	elastography to Predict Esophageal Varices in patients with
T-25 Xingshun Qi China Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis No association of homocysteine, anticardiolipin antibody, and anti-β2 glycoprotein I antibody with portal venous system thrombosis in liver cirrhosis T-27 Sherief Abd-Elsalam Egypt Prophylaxis of Spontaneous Bacterial Peritonitis: A Randomized Trial T-28 Jeong Han Kim South Korea One month and three month readmission rates in cirrhotic patients were not changed during past seven years Outcomes of early versus delayed endoscopy in cirrhotic patients with acute variceal bleeding: A systematic review and metaanalysis T-31 Xingshun Qi China Portal venous system thrombosis after bariatric surgery: A systematic review and meta-analysis T-32 Masood Muhamm Karim Pakistan Portosystemic Encephalopathy (PSE) recurrence in cirrhotic	330	Hyperte	T-24	Julius	Spicak	Czech Republic	elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis
T-26 Xingshun Qi China β2 glycoprotein I antibody with portal venous system thrombosis in liver cirrhosis Norfloxacin with Itopride versus Norfloxacin alone in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis: A Randomized Trial Jeong Han Kim South Korea One month and three month readmission rates in cirrhotic patients were not changed during past seven years Outcomes of early versus delayed endoscopy in cirrhotic patients with acute variceal bleeding: A systematic review and metaanalysis T-31 Xingshun Qi China Portal venous system thrombosis after bariatric surgery: A systematic review and meta-analysis T-32 Masood Muhami Karim Pakistan	331	ortal	T-25	Xingshun	Qi	China	
T-27 Sherief Abd-Elsalam Egypt Prophylaxis of Spontaneous Bacterial Peritonitis: A Randomized Trial T-28 Jeong Han Kim South Korea One month and three month readmission rates in cirrhotic patients were not changed during past seven years Outcomes of early versus delayed endoscopy in cirrhotic patients with acute variceal bleeding: A systematic review and meta-analysis T-31 Xingshun Qi China Portal venous system thrombosis after bariatric surgery: A systematic review and meta-analysis T-32 Masood Muham Karim Pakistan Portosystemic Encephalopathy (PSE) recurrence in cirrhotic	332	Pc	T-26	Xingshun	Qi	China	
334 T-28 Jeong Han Kim South Korea patients were not changed during past seven years Outcomes of early versus delayed endoscopy in cirrhotic patients with acute variceal bleeding: A systematic review and meta-analysis T-31 Xingshun Qi China Portal venous system thrombosis after bariatric surgery: A systematic review and meta-analysis T-32 Masood Muhami Karim Pakistan Portosystemic Encephalopathy (PSE) recurrence in cirrhotic	333		T-27	Sherief	Abd-Elsalam	Egypt	Prophylaxis of Spontaneous Bacterial Peritonitis: A Randomized
T-29 Xingshun Qi China with acute variceal bleeding: A systematic review and meta- analysis T-31 Xingshun Qi China Portal venous system thrombosis after bariatric surgery: A systematic review and meta-analysis Portosystemic Encephalopathy (PSE) recurrence in cirrhotic	334		T-28	Jeong Han	Kim	South Korea	
336 I-31 Xingshun Qi China systematic review and meta-analysis T-32 Masood Muhami Karim Pakistan Portosystemic Encephalopathy (PSE) recurrence in cirrhotic	335		T-29	Xingshun	Qi	China	with acute variceal bleeding: A systematic review and meta- analysis
337 I-32 Masood Muhami Karim Pakistan	336		T-31	Xingshun	Qi	China	systematic review and meta-analysis
	337		T-32	Masood Muham	Karim	Pakistan	

No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
338		T-33	Haryono	Haryono	Indonesia	Prediction of Esophageal Varices Grading in Cirrhotic Patients using Liaoning, Albumin-Bilirubin and Platelets-Albumin-Bilirubin Score
339		T-34	Adinda	Rahadini	Indonesia	Presence of Atrial Fibrillation is Associated with Increased Mortality Risk in Cirrhosis Patients: Meta Analysis
340		T-35	Kessarin	Thanapirom	Thailand	Prevalence, characteristics and prognosis of bacterial infection in patients with decompensated cirrhosis and acute-on-chronic liver failure: a multi-center study
341		T-36	Arunchai	Chang	Thailand	Role of lactulose for prophylaxis on hepatic encephalopathy in cirrhotic patient presented with upper gastric intestinal bleeding
342		T-37	Asif.N.	Iqbal	India	Rule Of 15: A New Diagnostic Tool To Differentiate Benign And Malignant Portal Vein Thrombus (Pvt)
343	sis	T-38	Neeraj	Singla	India	SARC-F score: A quick bedside questionnaire to assess sarcopenia in Cirrhosis
344	Cirrho	T-39	Xingshun	Qi	China	Spontaneous splenorenal shunt may decrease the long-term survival of liver cirrhosis by compromising liver volume
345	tions of	T-40	Jigar	Patel	India	Study Of The Role Of Non-Invasive Markers As Predictor Of Esophageal Varices In Cirrhosis Of Liver (Scientific)
346	omplica	T-41	Bogi	Wibowo	Indonesia	The Association Between Hepatic Cirrhosis Complications and Total Lymphocyte Count in Hepatic Cirrhosis Patients at Saiful Anwar Hospital Malang
347	er C	T-42	Ahmad Fariz Mal	Zein	Indonesia	The clinical profiles and in-hospital clinical outcome in young adult patients with esophageal varices: one-year observation
348	Hypertension and Other Complications of Cirrhosis	T-43	Manami	Yoshida	Japan	The Effectiveness Of Oral Thrombopoietin Receptor Agonist, Lusutrombopag For The Treatment Of Thrombocytopenia In Chronic Liver Disease Patients Undergoing Invasive Procedure In Japan.
349	nsior	T-44	Syed	Ali	Pakistan	The Etiology Of Upper Gastrointestinal Bleeding In Patients Presenting To A Tertiary Care Hospital, Karachi, (Scientific)
350		T-45	Heng	Du	China	The Risk Factors Influencing The 1-Year Survival Of The Patients With Transjugular Intrahepatic Portosystemic Shunt (Tips)
351	Portal	T-46	Peng	Chen	China	The value of platelet parameters and related scoring system in predicting esophageal varices and collateral veins in patients with liver cirrhosis
352		T-47	Jalpa	Devi	Pakistan	Thirty-Day Readmission after Esophageal Variceal Hemorrhage and Its Impact on Outcomes in the Tertiary care Hospital
353		T-48	Dipen	Agrawal	India	To Study the prevalence of Hepato-Adrenal Syndrome & low HDL value<40 mg/dl in hemodynamically stable liver cirrhotic patients
354		T-49	Dipen	Agrawal	India	To Study The Prevalence Of Hepato-Adrenal Syndrome In Hemodynamically Stable Liver Cirrhotic patients
355		T-50	Takamasa	Ohki	Japan	Tolvaptan improved not only hepatic edema or ascites but also overall survival in decompensated cirrhosis patients
356		T-51	Rattaya	Janyajirawong	Thailand	Efficacy of zinc supplement in minimal hepatic encephalophathy : A prospective, randomized controlled trial

No	Theme	Poster Board	First Name	Last Name	Country	Paper Title
357	_	T-52	Keerati	Kiattikunrat	Thailand	The Impact Of Frailty On Decompensation And Survival In Patients With Cirrhosis: A Prospective Cohort Study
358	and Other Cirrhosis	T-53	Hyung Jun	Kim	South Korea	Repeated versus Single Treatment of Esophageal Variceal Ligation after Esophageal Variceal Bleeding: Multicenter Retrospective Study
359	Portal Hypertension and Oth Complications of Cirrhosis	T-54	Rohit	Mehtani	India	Hepatic Encephalopathy in ACLF – Is intravenous BCAA the answer? Interim analysis of the BCAA-ACLF Trial
360	Hyperi plicat	T-55	Rohit	Mehtani	India	Utility of Bispectral Index for objective assessment of Hepatic Encephalopathy in Acute on Chronic Liver Failure
361	tal I	T-56	Padmanabhan	Purushothaman	India	Platelets In Chronic Liver Disease: Beyond Numbers
362	Por	T-57	Hae Won	Yoo	South Korea	The prediction of liver decompensation using hepatic collagen deposition assessed by computer-assisted image analysis with Masson-trichrome stain
363	tion ent)	U-01	Muhammad Ali	Qadeer	Pakistan	Assessing the knowledge of trainee residents for liver involvement and related issues in COVID-19 pandemic.
364	and Education Development)	U-02	Tiffany	Hensley-mcbain	United States	Point-of-Care Interactive Decision Support Tool Demonstrates Discordance Between Healthcare Practitioner Approaches and APASL Guideline Recommendations in the Management of HBV Infection
365	Training a	U-03	Shoukat	Ali	Pakistan	Restarting Endoscopy Services In Pakistan In Covid Era: The Way Forward
366	Trai (Ca	U-04	Sureeporn	Jangsirikul	Thailand	Video-assisted Liver Ultrasound Training for Non-radiologists